Clinical Trials
1.1k
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (436 trials with phase data)β’ Click on a phase to view related trials
Platelet Volunteers, Longitudinal and Multi-omic Study
- Conditions
- Thrombosis
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-10-02
- Target Recruit Count
- 400
- Registration Number
- NCT07137429
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
EDEN Intracardiac Electrogram Recording and Classifying System
- Conditions
- Ventricular Arrhythmia
- First Posted Date
- 2025-08-22
- Last Posted Date
- 2025-10-02
- Target Recruit Count
- 50
- Registration Number
- NCT07137455
- Locations
- πΊπΈ
Emory University Hospital, Atlanta, Georgia, United States
Molecular and Clinical Analysis of Bone Marrow Failure: A Secondary Research Study
- Conditions
- Bone Marrow Failure DisordersMyelodysplastic SyndromesVEXAS SyndromeHemoglobinurea, ParoxysmalBone Marrow Diseases
- First Posted Date
- 2025-08-05
- Last Posted Date
- 2025-09-15
- Target Recruit Count
- 1400
- Registration Number
- NCT07102849
- Locations
- πΊπΈ
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Healing Within: Mindfulness Smoking Cessation Intervention
- Conditions
- Smoking Cessation
- First Posted Date
- 2025-06-10
- Last Posted Date
- 2025-08-11
- Target Recruit Count
- 48
- Registration Number
- NCT07013968
- Locations
- πΊπΈ
Black Hills Center for American Indian Health, Rapid City, South Dakota, United States
Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-10-02
- Target Recruit Count
- 30
- Registration Number
- NCT06948097
- Locations
- πΊπΈ
Stanford University School of Medicine, Stanford, California, United States
πΊπΈNational Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
πΊπΈUniversity of Utah Health, Salt Lake City, Utah, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 226
- Next
News
FDA Grants Priority Review to Omidubicel for Severe Aplastic Anemia Treatment
The FDA has accepted Ayrmid Ltd.'s priority review application for omidubicel as a treatment for severe aplastic anemia, with a PDUFA target action date of December 10, 2025.
FDA Approves HemiClor: First Low-Dose Chlorthalidone Tablet for Hypertension Management
The FDA has approved HemiClor (12.5 mg chlorthalidone), the first low-dose formulation of this thiazide-like diuretic available in the U.S. for treating hypertension in adults.
Tonsil Removal Reduces Healthcare Needs in Children with Mild Sleep-Disordered Breathing
A new clinical trial shows adenotonsillectomy in children with mild sleep-disordered breathing reduces doctor visits by 32% and medication use by 48% within the first year after surgery.
NIH Funding Critical for Addressing Gaps in Pediatric Clinical Trials, Study Reveals
A comprehensive analysis of 4,527 clinical trials from 2015-2020 reveals that less than half of trials, whether NIH or industry-funded, focus on the top 20 childhood disease categories.
NIH-Funded BEST-ICU Trial Explores Behavioral Economics to Enhance Critical Care Bundle Implementation
The BEST-ICU trial, funded by NIH Collaboratory and NHLBI, investigates behavioral economics-based strategies to improve adoption of the evidence-based ABCDEF bundle in intensive care units.
IVOS Medical Secures $1.9M NIH Grant for BOSS G4 Video Laryngoscope Development
IVOS Medical has been awarded a $1.9M Phase II SBIR grant from the NIH to advance its IVOS BOSS G4 video laryngoscope, designed for improved airway management.
Fostamatinib Fails to Improve COVID-19 Recovery in Hospitalized Patients
A recent international trial found that fostamatinib, an immune-suppressing drug, did not significantly improve outcomes for hospitalized COVID-19 patients.
Nudge Trial: Text Message Reminders Fail to Improve Cardiovascular Medication Adherence
A pragmatic clinical trial, Nudge, found that text message reminders did not significantly improve cardiovascular medication adherence compared to usual care.
NIH Collaboratory Trials BEST-ICU and Chat 4 Heart Health Transition to Implementation Phase
The BEST-ICU trial, supported by the National Heart, Lung, and Blood Institute, is now in the implementation phase, focusing on improving care for critically ill adults by increasing ABCDEF bundle adoption.
Pomalidomide Shows Promise in Reducing Bleeding for Hereditary Hemorrhagic Telangiectasia
A Phase II clinical trial (PATH-HHT) demonstrated that pomalidomide significantly reduces the severity of nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT).